Vititoe Sarah E, Govil Priya, Baglivo Aidan, Beebe Elisha, Garry Elizabeth M, Gatto Nicolle M, Lasky Tamar, Chakravarty Aloka, Bradley Marie C, Perez-Vilar Silvia, Rivera Donna R, Quinto Kenneth, Clerman Andrew, Rajpal Anil, Frajzyngier Vera
Aetion, Inc, Scientific Research and Strategy, New York, New York, USA.
Office of the Commissioner, US Food and Drug Administration, Silver Spring, Maryland, USA.
Open Forum Infect Dis. 2023 Jul 10;10(7):ofad339. doi: 10.1093/ofid/ofad339. eCollection 2023 Jul.
There is a dearth of drug utilization studies for coronavirus disease 2019 (COVID-19) treatments in 2021 and beyond after the introduction of vaccines and updated guidelines; such studies are needed to contextualize ongoing COVID-19 treatment effectiveness studies during these time periods. This study describes utilization patterns for corticosteroids, interleukin-6 (IL-6) inhibitors, Janus kinase inhibitors, and remdesivir among hospitalized adults with COVID-19, over the entire hospitalization, and within hospitalization periods categorized by respiratory support requirements.
This descriptive cohort study included United States adults hospitalized with COVID-19 admitted from 1 January 2021 through 1 February 2022; data included HealthVerity claims and hospital chargemaster. The number and distribution of patients were reported for the first 3 drug regimen lines initiated.
The cohort included 51 066 patients; the most common initial drug regimens were corticosteroids (23.4%), corticosteroids plus remdesivir (25.1%), and remdesivir (4.4%). IL-6 inhibitors and Janus kinase inhibitors were included in later drug regimens and were more commonly administered with both corticosteroids and remdesivir than with corticosteroids alone. IL-6 inhibitors were more commonly administered than Janus kinase inhibitors when patients received high-flow oxygen or ventilation.
These findings provide important context for comparative studies of COVID-19 treatments with study periods extending into 2021 and later. While prescribing generally aligned with National Institutes of Health COVID-19 treatment guidelines during this period, these findings suggest that prescribing preference, potential confounding by indication, and confounding by prior/concomitant use of other therapeutics should be considered in the design and interpretation of comparative studies.
在2021年及之后引入疫苗和更新指南后,关于2019冠状病毒病(COVID-19)治疗的药物利用研究匮乏;需要此类研究来了解这些时间段内正在进行的COVID-19治疗效果研究的背景情况。本研究描述了COVID-19住院成人患者在整个住院期间以及按呼吸支持需求分类的住院期间,皮质类固醇、白细胞介素-6(IL-6)抑制剂、Janus激酶抑制剂和瑞德西韦的使用模式。
这项描述性队列研究纳入了2021年1月1日至2022年2月1日因COVID-19住院的美国成年人;数据包括HealthVerity索赔和医院收费主表。报告了启动的前3种药物治疗方案系列的患者数量和分布情况。
该队列包括51066名患者;最常见的初始药物治疗方案是皮质类固醇(23.4%)、皮质类固醇加瑞德西韦(25.1%)和瑞德西韦(4.4%)。IL-6抑制剂和Janus激酶抑制剂包含在后续药物治疗方案中,与单独使用皮质类固醇相比,它们更常与皮质类固醇和瑞德西韦联合使用。当患者接受高流量氧气或通气时,IL-6抑制剂的使用比Janus激酶抑制剂更常见。
这些发现为COVID-19治疗的比较研究提供了重要背景,这些研究的时间段延伸至2021年及以后。虽然在此期间的处方总体上符合美国国立卫生研究院的COVID-19治疗指南,但这些发现表明,在比较研究的设计和解释中,应考虑处方偏好、潜在的适应症混杂以及其他治疗药物的既往/同时使用造成的混杂。